The treatment being studied involves a combination of two medications: MK-1084 and pembrolizumab. Pembrolizumab is also known by the brand name KEYTRUDA and is given as an infusion, which means it is delivered directly into the bloodstream through a vein. MK-1084 is taken as a tablet. Some participants in the study will receive pembrolizumab with MK-1084, while others will receive pembrolizumab with a placebo, which looks like the real medication but does not contain any active ingredients. The purpose of the study is to compare the effectiveness of these two treatment combinations.

Participants in the study will receive their assigned treatment and will be monitored over a period of time to see how their cancer responds. The study will look at how long participants live without their cancer getting worse, known as progression-free survival, and overall survival, which is the length of time participants live after starting the treatment. The study will also track any side effects experienced by participants and how the treatment affects their quality of life. This information will help researchers understand the potential benefits and risks of the new treatment combination for people with this specific type of lung cancer.

The main goal is to determine whether the medicine is safe and can effectively fight the cancer. Participants will start with low amounts of the tablet and gradually receive higher amounts in a step‑wise manner (dose escalation) to find the most suitable dose. Throughout the study, regular visits will include simple checks such as blood work, heart rhythm recordings, and imaging scans to see how the tumor responds.

During the trial, participants will have their vital signs, laboratory results, and any side effects carefully recorded. Imaging studies will be performed at set intervals to measure changes in tumor size, which helps assess the drug’s ability to shrink or control the cancer (antitumor activity). All procedures are designed to monitor safety and determine the optimal dose for future research.

The purpose of the study is to learn how the immune system changes and to find measurable signs (biomarkers) that show whether the tumors are responding when the two drugs are given together, and also to see the early effect of the combination on tumor control. Participants receive a series of IV infusions of the drugs over several weeks while blood and small tissue samples are taken to look at immune cells and other markers; doctors watch for any side effects and track the condition of the cancer through regular scans. Terms such as Treg refer to a type of immune cell that can suppress immune activity, and PD-(L)1–refractory describes tumors that do not respond to treatments that target the PD‑1/PD‑L1 pathway. The study continues until the planned follow‑up period is completed.

The main aim is to see whether the medicine can keep the cancer from coming back compared with the placebo, measured by the length of time patients stay free of disease, known as DFS. Participants will take the study medication for a set period, return for regular check‑ups, and have routine tests such as scans and lab work to monitor their health.

In addition to tracking if the cancer returns, the study will also look at overall survival, which is how long participants live after treatment, referred to as OS, and whether the disease spreads to the CNS. Safety will be watched by recording any side effects using a standard grading system (CTCAE) and by performing simple heart rhythm checks (ECG). The study follows participants for several years to gather this information.

The purpose of the study is to evaluate safety and find the best dose of the new medicines when used alone or in combination. Participants receive an IV infusion, which means the medicine is delivered directly into a vein, and they swallow tablets on a regular schedule. Treatment cycles are repeated every few weeks, and patients return to the clinic for regular check‑ups, blood tests, and simple examinations to watch for any side effects.

Participants receive three cycles of the infusion, each given several weeks apart, and then are monitored for signs that the disease returns or worsens. Follow‑up includes regular scans and doctor visits to check for any new growths, side effects, or overall health changes. The study records the time until any cancer recurrence, any death related to the disease, and any serious side effects, using standard criteria such as RECIST 1.1 to measure tumor changes.

Participants will receive the assigned tablet daily and the infusion every few weeks, with regular clinic visits for safety checks, blood tests and imaging scans such as CT scans to look for changes in tumor size. The study will continue until the disease gets worse, a participant stops treatment, or the trial ends. Researchers will record how long the cancer stays stable (progression‑free survival), overall survival, side effects, and quality‑of‑life questionnaires.

The main purpose of the trial is to keep participants who are still benefiting from the drug under medical supervision while safety is monitored. After joining, participants will continue to receive opnurasib on a regular schedule for as long as it remains helpful and tolerable. Visits will include simple check‑ups to record any side effects, any changes in dosage, and overall health. The study does not involve any additional invasive procedures beyond the usual care for this condition.

The main goal of the trial is to learn how safe the medicine is and how well patients can tolerate increasing doses. Participants will receive the drug in a series of treatment cycles that last about four weeks each, with the amount of medicine gradually increased in early groups to find the highest dose that can be given without unacceptable side effects.

During the study, patients will have regular check‑ups, blood tests, and scans to watch for any side effects and to see how the cancer responds. Any problems that arise will be recorded and managed by the medical team, and the study will continue until the predetermined number of treatment cycles is completed or if a participant chooses to stop early.

The study compares different treatment combinations in adults who have not yet received treatment for this cancer. Treatment is given in cycles, with medicine taken or infused over repeated visits. After the first part of treatment, the study continues with follow-up while treatment is ongoing, to watch for side effects and other health changes. Some people may receive different combinations as part of the study design.

Pemetrexed, cisplatin, and carboplatin are chemotherapy medicines, which are drugs used to kill cancer cells. Pembrolizumab is an immunotherapy medicine, which helps the body’s own defense system attack cancer cells. Intravenous means the medicine is given through a vein.

People in the study are assigned to one of the two medicines. The treatment is given over time as intravenous infusions, which means medicine is put directly into a vein. The study is double-blind, which means the people taking part and the study doctors do not know which treatment is being given. During the study, doctors follow how the cancer changes, watch for side effects, and check how well each medicine is tolerated.

The study has more than one part. In the first part, small groups of people receive the drug combinations so that researchers can watch for side effects and choose a dose that can be used more widely. In the later part, more people receive the combinations to learn more about how the treatment works in the different cancer groups and to compare dose options in some groups. Because this is an open-label trial, everyone knows which treatment is being given.

During the trial, the treatment is given over time, and participants are followed closely while they are receiving it and for a period afterward. Doctors check for side effects, how well the cancer seems to respond, and how the body handles the drugs. The study includes people with several cancer types, and the treatment plan may differ depending on the cancer group and the study part.

People in the study receive the same cancer treatment, but pembrolizumab is started at different times of day. One group receives it in the morning, between 08:00 and 12:00, and the other group receives it in the afternoon, between 13:00 and 17:00. Treatment is then continued over several cycles, with regular medical checks during the study. The study looks at survival, cancer growth, side effects, and how treatment affects daily well-being and sleep.

The study is a randomized phase III trial, which means the treatment timing is assigned by chance and the treatment plan is being tested in a larger group of patients. The study is designed for adults with advanced lung cancer and will follow results over time to compare the two timing schedules.

Participants may receive combinations of several medications, including the experimental drug rilvegostomig and the medication ramucirumab. Other medicines that may be part of the treatment plan include mycophenolate mofetil and infliximab. These medications are administered through different methods, such as oral pills taken by mouth or IV infusion, which is a process where medicine is delivered directly into a vein through a tube.

During the study, the way the body processes these drugs and how the immune system reacts to them will be monitored. The research will look at how well the treatments work by observing changes in the size of tumors and how long the cancer remains stable. Researchers will also track any adverse events, which are unwanted or harmful side effects that may occur during treatment.

Participants in the study will receive these medications through intravenous infusion, which means the medicine is delivered directly into a vein. The research is divided into different stages to determine the safest and most effective dose of the medicine. During the first part, the focus is on how well the body tolerates the combination of drugs. The subsequent parts aim to see how well the treatments work to reduce the size or growth of the tumors.

One group will receive sotorasib combined with a platinum doublet, which refers to a combination of two drugs like carboplatin and pemetrexed. The other group will receive pembrolizumab along with the same platinum doublet. Other medications, such as folic acid, hydroxocobalamin, dexamethasone, and antiemetics, may be used to support the treatment and manage side effects. During the study, the time until the cancer grows or worsens and the total length of time patients live are monitored.

The purpose of the study is to characterize the pharmacokinetics, which describes how a drug moves through the body, specifically for the subcutaneous version of the medicine. Participants will be monitored to ensure the safety of this administration method and to see how much of the medicine stays in the bloodstream over time. During the course of the study, different doses may be used to determine the most appropriate amount for patients.

The purpose of the study is to determine how well this new drug works and to monitor its safety in people with this condition. During the study, participants will receive the medication, and their health will be closely monitored. This includes checking for any side effects and observing how the cancer responds to the treatment over time.

The treatments involve medications administered through an Intravenous line, which is a method of delivering medicine directly into a vein. One group receives the study drug PF-08634404 along with a combination of chemotherapy drugs, which may include Paclitaxel, Carboplatin, or Pemetrexed. Another group receives Pembrolizumab combined with these chemotherapy drugs. Some participants may also receive Paclitaxel Albumin-Bound or a Placebo involving Sodium Chloride. During the study, participants will be monitored to see how they respond to the medicines and to track their Overall Survival and Progression-Free Survival, which refers to the length of time during and after treatment that a person lives with the disease without it getting worse.

Participants may receive several different medications. These include cetuximab, which is given through an intravenous infusion, a method of delivering medicine directly into a vein, and MK-1084, which is taken as a pill. Other medications being studied include pembrolizumab, also given by intravenous infusion. Some people may receive a combination of these new drugs, while others may receive standard treatments like carboplatin or pemetrexed.

During the study, different groups of participants will be assigned to receive different combinations of these medicines to see which ones work best. The process involves regular monitoring to see how the body reacts to the treatments and how the cancer changes over time.

The cancer being investigated is also classified as advanced or metastatic, meaning it has grown beyond the original part of the lung or has spread to other parts of the body. Participants in this trial will receive their treatment through intravenous use, which involves delivering the medication directly into a vein using a liquid solution for infusion. The study will monitor how long the cancer remains stable without growing and the overall length of time patients live during the trial.

The study is divided into two parts to determine the best way to use these medicines. In the first part, different amounts of the drugs are given to find the safest and most effective dose. The second part focuses on finding the optimal dose and observing how well the combination works for different types of lung cancer. Throughout the process, the safety and how the body processes the drugs are closely monitored.

The purpose of the study is to compare the effectiveness of these treatment combinations in patients with advanced NSCLC who have previously been treated with other therapies. Participants will be randomly assigned to one of the three treatment groups. The treatments will be given as an infusion, which means they are administered directly into the bloodstream through a vein. The study will monitor the participants over a period to assess how well the treatments work and to observe any side effects.

Throughout the study, participants will receive regular check-ups and monitoring to ensure their safety and to track the progress of the treatment. The study aims to provide valuable information on the potential benefits and risks of these treatment combinations for people with advanced Non-Small Cell Lung Cancer.

During the study, healthy adult males will receive a single dose of [14C]-zipalertinib in the form of an oral suspension, which is a liquid medicine taken by mouth. After taking the dose, participants will provide samples of plasma, which is the liquid part of the blood, and whole blood to measure the concentration of the drug. Additionally, samples of urine and feces will be collected to track how the substance is cleared from the system.

The research involves monitoring how the drug is distributed and how it changes over time within the body. Scientists will examine the levels of the drug in different biological fluids to create a complete profile of its behavior. This information helps in understanding how the medicine might eventually be used to treat patients safely and effectively.

The treatment involves the intravenous administration of SGN-ALPV, meaning the medicine is delivered directly into a vein through a needle or tube. Participants in the study will receive the drug in different amounts to help researchers determine the highest dose that can be given safely without causing too many side effects. During the study, medical professionals will monitor how the body reacts to the medication and how much of the drug remains in the bloodstream over time.

The study is conducted using oral use, meaning the medication is taken by mouth in the form of a tablet. Participants will receive a single dose of 240 mg of the medication while in a fasted state, which means they have not eaten for a certain period before taking the drug. The study follows a crossover design, where participants receive different versions of the medication at different times to allow for direct comparison.

The purpose of the study is to see how effective and safe these treatments are for patients with this type of lung cancer. Participants will receive either rilvegostomig or pembrolizumab, along with chemotherapy drugs such as carboplatin and paclitaxel. The study will monitor how long patients live and how long they remain free from cancer progression, which means the cancer does not get worse. The study will also look at other factors like the overall response to the treatment and any side effects experienced.

Participants will receive their treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will take place over several months, and participants will have regular check-ups to monitor their health and the effects of the treatment. The goal is to find out which combination of treatments works best for this type of lung cancer.

The purpose of the study is to find out if firmonertinib works better than the doctor’s choice of osimertinib or afatinib in stopping the cancer from getting worse, and to see how many people respond to the treatment. The study will also look at how safe these medicines are and what side effects they may cause. People taking part will receive one of these medicines as their first treatment for cancer that has spread or grown too much to be cured by surgery or radiation.

During the study, people will be divided into groups by chance, similar to flipping a coin, and will receive either firmonertinib or the doctor’s choice of osimertinib or afatinib. Treatment can continue for up to 18 months or longer if the medicine is helping to control the cancer. Throughout the study, doctors will monitor how well the treatment is working and check for any side effects. Both the people in the study and their doctors will know which medicine is being given, as this is not a blinded study.

The study is divided into different parts. The first part will test different dose levels of the investigational medications to find the most suitable dose for further testing. During this phase, doctors will carefully monitor participants for any side effects. The following parts of the study will test the chosen dose in larger groups of people with advanced non-small cell lung cancer to better understand how well the treatment works and how safe it is. Throughout the study, participants will receive the medications through infusion into a vein. Doctors will regularly check how the cancer responds to treatment using imaging scans and other assessments.

During the study, participants will need to provide a tissue sample from their tumor, either from a previously stored sample or from a new biopsy if needed. The study will track various aspects of participant health and treatment response, including any side effects that occur, whether the cancer shrinks or stops growing, and how long any positive effects last. Blood samples will be collected at different times to measure the levels of the investigational medications in the body and to check whether the immune system develops a response to these medications.

The purpose of the study is to find out if this treatment is safe and to determine the best dose that patients can tolerate. The study will also look at whether the treatment helps to control or shrink the tumors. Patients in this study must have tumors that show the presence of the CLDN6 protein and must have cancer that has spread or cannot be removed by surgery. The treatment is given through an infusion into a vein. During the study, doctors will closely monitor patients for any side effects and will measure how the tumors respond to the treatment using imaging scans or blood tests that measure certain markers in the blood.

The study will follow patients for several years to understand the long-term effects of the treatment and how well it works over time. Doctors will collect blood samples to measure changes in the immune system and to see how long the modified immune cells stay in the body. The study will test different doses of the cell therapy and the vaccine to find the most appropriate amount to use in future studies. Some patients will receive treatment made using a manual process while others will receive treatment made using an automated process to compare whether both methods work similarly.

The purpose of this study is to compare how well the combination of STK-012 with chemotherapy works compared to chemotherapy alone in people whose cancer has a specific characteristic related to a marker called PD-L1. The study will look at how many people respond to the treatment, meaning their tumors shrink or disappear. During the study, participants will receive their assigned treatment over a period of time, with regular check-ups to monitor how the cancer is responding and to check for any side effects. The study will also measure how long people live without their cancer getting worse and how long they live overall. Blood tests and other assessments will be done to understand how the experimental medicine works in the body and whether it causes the body to produce antibodies against it.

This study is designed for people who have advanced lung cancer that has spread to other parts of the body or cannot be treated with surgery or radiation. Participants must not have received previous treatment for their advanced cancer, although they may have had treatment after surgery if it was completed more than six months before joining the study. The study will include people whose tumors do not have certain genetic changes for which other standard treatments are available. Participants will need to be well enough to carry out normal daily activities and have adequate organ function based on blood tests.

The purpose of this study is to find out if romiplostim can help maintain platelet counts high enough to allow patients to receive their full chemotherapy doses on time without delays or reductions. The study will compare romiplostim with placebo to measure its effectiveness. Participants entering the study must have a platelet count at or below a certain level and must have at least three more cycles of chemotherapy planned. The chemotherapy cycles are given every 21 or 28 days depending on the specific treatment plan.

During the study, participants will receive either romiplostim or placebo as an injection under the skin while continuing their regular chemotherapy treatment. The study medication will be given for a treatment period lasting up to 12 weeks. Doctors will monitor platelet counts, track whether chemotherapy doses need to be changed due to low platelets, and watch for any bleeding problems or other side effects. Participants will continue to be followed for safety monitoring for up to 36 months to check for any long-term effects.

The purpose of this study is to see if this imaging method can help doctors find out whether the cancer has spread to lymph nodes, which are small bean-shaped organs that are part of the body’s defense system, or to other parts of the body that are far from where the cancer started. The study will look at patients who have not received any treatment yet, as well as patients who have already had surgery, radiation therapy, or other treatments for their lung cancer and might have cancer that has come back.

During the study, patients will receive a single injection of the substance and then have imaging scans taken to see how well the substance shows areas of cancer in the body. Doctors will measure how much of the substance collects in different areas and will compare the scan results with tissue samples taken from suspected cancer areas to confirm whether cancer is present. The study aims to determine if this imaging approach can be useful in understanding where the cancer is located and whether it has spread.

The purpose of this study is to investigate the cardiovascular side effects of immune checkpoint inhibitors, which means looking at how these cancer treatments might affect the heart and blood vessels. The study will monitor patients who are receiving these treatments as part of their regular cancer care. During the study, doctors will check for various heart-related problems that might develop or get worse during treatment. The treatment period with these medicines can last up to twelve months.

The main focus of the study is to track serious heart-related events, including death from heart problems, heart attacks, strokes, chest pain that requires hospital care or urgent treatment to restore blood flow to the heart, and hospital stays due to heart failure (when the heart cannot pump blood well enough). The study will also look at other heart and blood vessel problems such as new or worsening high blood pressure, irregular heartbeats, blood clots in the veins, and other heart-related issues that require hospital admission. This research aims to better understand how these cancer treatments affect the heart and blood vessels so that doctors can better monitor and care for patients receiving these medicines.

The purpose of this study is to gather information that will help plan a larger study in the future. Researchers want to compare how well the new imaging substance 68Ga-FAPI-46 works compared to the standard method that uses fludeoxyglucose (18F) and brain MRI for finding cancer that has spread to other parts of the body in patients who have been newly diagnosed with non-small cell lung cancer. The study will look at how many cancer spots are found with each method and where these spots are located in the body.

During the study, patients will receive scans with both imaging substances. They will first have or will have already had a scan with fludeoxyglucose (18F) as part of their regular care. Within three weeks, they will also receive a scan using 68Ga-FAPI-46. If a brain MRI has not already been done, patients will also undergo this scan. Doctors will then compare the results from both types of scans to see if the new substance finds cancer spots that the standard method might miss, or if the standard method finds spots that the new substance does not detect.

During the study, patients will be divided into two groups. One group will receive cemiplimab alone, while the other group will receive cemiplimab together with chemotherapy. Before starting treatment, patients will have imaging scans performed to measure their cancer. These scans will be repeated at specific times during the study to see how the cancer is responding to treatment. Blood samples will also be collected to look at certain markers in the blood that might help doctors understand why some cancers grow quickly after treatment starts. The study looks specifically at a type of immune cell in the blood that may be connected to how the cancer responds to treatment.

The study will track several outcomes including how many patients experience rapid cancer growth, how many patients respond to treatment with their tumors shrinking, how long patients live without their cancer getting worse, and overall survival time. The study will also carefully monitor any side effects or unwanted reactions that patients may experience from the medications. Information gathered from imaging scans, blood tests, and tissue samples will help researchers better understand which patients might benefit most from receiving cemiplimab alone versus cemiplimab with chemotherapy.

The purpose of this study is to find out if zongertinib works better than standard of care treatment in preventing the cancer from coming back after surgery. The study will measure how long patients live without their cancer returning, which is called disease-free survival. The study will also look at how long patients live overall and will check for any serious side effects from the treatments. Patients in this study will be randomly assigned to receive either zongertinib or one of the standard of care treatments, or they may be observed without additional treatment after surgery.

During the study, patients will be monitored regularly to check if the cancer comes back and to watch for any side effects from the treatment. The treatment with zongertinib can last up to 36 months, while the standard of care treatments can last up to 12 months. Patients will need to have their cancer tissue tested to confirm that it has the specific HER2 mutations required for the study. The study will follow patients for several years to gather information about whether the treatment helps keep the cancer from returning and to understand the safety of the medications being tested.

The study is divided into two parts. The first part will test different doses of OMTX705 when combined with the other three medications to find a safe dose that can be used in the second part. During this phase, doctors will carefully monitor patients for any side effects and determine the best dose to use. The second part of the study will compare the combination of all four medications to a treatment that does not include OMTX705. This comparison will help researchers understand if adding OMTX705 to the standard treatment makes the treatment work better.

Throughout the study, participants will have regular check-ups, blood tests, and imaging scans to monitor how the cancer responds to treatment and to check for any side effects. The study aims to find out if this combination of medications is safe and if it can help shrink tumors or slow down the growth of cancer. Researchers will also look at how long patients live without their cancer getting worse and how long they survive overall. Blood samples will be collected to measure the levels of the medications in the body and to check if the body develops any immune response to OMTX705.

The purpose of the study is to find the best dose of izalontamab brengitecan in the first part of the study and then to compare how well this new treatment works compared to platinum-based chemotherapy in preventing the cancer from getting worse. The study is divided into two phases. In the first phase, researchers will look at the safety and effectiveness of different doses of izalontamab brengitecan to determine the recommended dose for the second phase. In the second phase, patients will be randomly assigned to receive either izalontamab brengitecan at the recommended dose or platinum-based chemotherapy, and the study will measure how long patients live without their cancer getting worse.

During the study, patients will receive their assigned treatment through infusions into a vein, with some medications also given as injections under the skin. The treatments will be given in cycles over an extended period, and patients will be monitored regularly to check how the cancer responds to treatment and to watch for any side effects. The study will collect information about survival, how long the cancer stays under control, and the overall safety of the treatments being tested.